HC Wainwright & Co. Maintains Buy on Cocrystal Pharma, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Cocrystal Pharma (NASDAQ:COCP) but has reduced the price target from $12 to $10.
January 03, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cocrystal Pharma's price target has been lowered from $12 to $10 by HC Wainwright & Co., although the Buy rating is maintained.
While the reduction in price target could suggest a more conservative outlook on the stock's future performance, the maintenance of a Buy rating indicates that the analyst still sees positive potential. This mixed signal may lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100